Evidence map›Paper›PMID 34981479›Full record

Trial reportAdvances in experimental medicine and biology2021

The Effects of Curcumin Plus Piperine Supplementation in Patients with Acute Myocardial Infarction: A Randomized, Double-Blind, and Placebo-Controlled Trial.

Samaneh Tabaee, Amirhossein Sahebkar, Tayebe Aghamohammadi, Manizhe Pakdel, Maryam Dehabeh, Reza Sobhani, Mona Alidadi, Muhammed Majeed, Seyed Reza Mirhafez

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. The Yin and Yang of copper in cardiovascular health and disease.Molecular and cellular biochemistry · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Samaneh Tabaee *Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Amirhossein Sahebkar *Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir.
Tayebe AghamohammadiNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Manizhe PakdelFaculty of Nursing, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Maryam DehabehNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Reza SobhaniNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Mona AlidadiDepartment of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Muhammed MajeedSabinsa Corporation, East Windsor, NJ, USA.
Seyed Reza MirhafezNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. mirhafezr@nums.ac.ir.
University of Neyshabur · IRNon-Communicable Diseases Research CenterBiotechnology Research Center · IRMashhad University of Medical Sciences · IRSabin Vaccine Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute myocardial infarction (AMI) is a leading cause of death and disability worldwide. Previous investigations have demonstrated that curcumin has a cardioprotective effect and may improve myocardial injury. So this study was performed to assess whether supplementation with curcumin could diminish myocardial injury following AMI.

methodsTo conduct this randomized, double-blinded, and placebo-controlled clinical trial, seventy-two patients with acute myocardial infarction, aged 18-75 years, were enrolled and randomly divided into the active intervention and control groups. The active intervention group (n = 38) received curcumin capsules with piperine supplement (500 mg/day, 95% curcuminoids) for 8 weeks, whereas the control group (n = 34) received a placebo capsule. At the baseline and end of the study, ejection fraction was assessed, and blood samples were taken from all patients to measure the levels of cardiac troponin I(cTnI), lipid profile, FBG, HbA1C, liver enzymes, renal function parameters, and electrolytes.

resultsIn this trial, curcumin supplementation significantly reduced the levels of HbA1C (-0.3 ± 2.2 vs. +1.1 ± 1.3, P = 0.002), LDL (-10.3 ± 20.7 vs. +0.2 ± 22.5, P = 0.039), ALT (-10.2 ± 28.5 vs. +7.3 ± 39.2, P = 0.029), and ALP (+6.4 ± 39.5 vs. +38.0 ± 69.0, P = 0.018) compared to the placebo group. Moreover, the serum concentration of HDL significantly improved in comparison with the placebo group (+4.5 ± 8.9 vs. -1.6 ± 7.7, P = 0.002). However, no substantial difference was perceived between the groups regarding the ejection fraction and serum levels of cTnI, FBG, renal function parameters, and electrolytes.

conclusionOur results indicated that daily intake of 500 mg of curcumin capsules with piperine supplement for 8 weeks modified lipid profile, liver enzymes, and glycemic status, but did not have any effect on ejection fraction and serum concentration of cardiac troponin I, renal function parameters, and electrolytes in acute myocardial infarction patients.

Indexed as

CurcuminMyocardial InfarctionAlkaloidsBenzodioxolesDietary SupplementsDouble-Blind MethodHumansPiperidinesPolyunsaturated AlkamidesAlkaloidsBenzodioxolesCurcuminPiperidinespiperinePolyunsaturated AlkamidesCardiac troponin IcTnI, ejection fractionCurcuminHbA1C, piperineLipid profileMyocardial infarction

Identifiers

PMID34981479
OpenAlexW4206402185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.